Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Up 6.6%

Share on StockTwits

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP)’s share price rose 6.6% on Tuesday . The stock traded as high as $0.82 and last traded at $0.81, approximately 421,700 shares were traded during mid-day trading. An increase of 38% from the average daily volume of 305,848 shares. The stock had previously closed at $0.76.

ADAP has been the topic of several analyst reports. Guggenheim cut shares of Adaptimmune Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, August 1st. Cowen reissued a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Thursday, November 7th. Zacks Investment Research cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. ValuEngine cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 17th. Finally, BidaskClub cut shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, July 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $6.59.

The company has a quick ratio of 3.93, a current ratio of 3.93 and a debt-to-equity ratio of 0.15. The firm has a market cap of $75.90 million, a P/E ratio of -0.84 and a beta of 1.70. The stock’s 50-day simple moving average is $0.99 and its 200 day simple moving average is $2.45.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.03). The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $7.00 million. On average, research analysts forecast that Adaptimmune Therapeutics PLC – will post -1.37 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of ADAP. Man Group plc boosted its position in Adaptimmune Therapeutics by 37.4% during the second quarter. Man Group plc now owns 1,839,225 shares of the biotechnology company’s stock valued at $7,394,000 after acquiring an additional 500,595 shares during the last quarter. Rathbone Brothers plc boosted its position in Adaptimmune Therapeutics by 146.6% during the second quarter. Rathbone Brothers plc now owns 704,472 shares of the biotechnology company’s stock valued at $2,832,000 after acquiring an additional 418,750 shares during the last quarter. Baillie Gifford & Co. boosted its position in Adaptimmune Therapeutics by 7.9% during the second quarter. Baillie Gifford & Co. now owns 4,143,840 shares of the biotechnology company’s stock valued at $16,658,000 after acquiring an additional 304,650 shares during the last quarter. Rock Springs Capital Management LP boosted its position in Adaptimmune Therapeutics by 9.4% during the second quarter. Rock Springs Capital Management LP now owns 875,000 shares of the biotechnology company’s stock valued at $3,518,000 after acquiring an additional 75,000 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its holdings in shares of Adaptimmune Therapeutics by 263.3% during the second quarter. DekaBank Deutsche Girozentrale now owns 89,000 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 64,500 shares during the period. 65.10% of the stock is currently owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Featured Story: Why do companies issue monthly dividends?

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Short Interest in Origin Bancorp Inc  Drops By 8.5%
Short Interest in Origin Bancorp Inc Drops By 8.5%
$0.17 Earnings Per Share Expected for Elevate Credit Inc  This Quarter
$0.17 Earnings Per Share Expected for Elevate Credit Inc This Quarter
Short Interest in Outlook Therapeutics, Inc.  Rises By 11.9%
Short Interest in Outlook Therapeutics, Inc. Rises By 11.9%
Happycoin Price Tops $0.0419
Happycoin Price Tops $0.0419
PlayChip  Price Hits $0.0006 on Major Exchanges
PlayChip Price Hits $0.0006 on Major Exchanges
INO COIN Trading Down 3.6% Over Last 7 Days
INO COIN Trading Down 3.6% Over Last 7 Days


© 2006-2019 Ticker Report